Are there benefits to adding IL5/IL5 receptor blockade in patients with vasculitic manifestations of EGPA?

While IL-5/IL5 receptor blockade has been shown to be efficacious in treating "eosinophilic" manifestations of EGPA, including asthma and nasal polyps, there are real-world studies that demonstrate its effectiveness in what we consider "vasculitic" manifestations of the disease as well. I personally believe that the distinction between vasculitic and eosinophilic manifestations is not clear-cut, and we know that eosinophils are a part of the vasculitic pathology. With that in mind, there is real-world data (Bettiol et al., PMID 34347947) that looked at 100 and 300 mg doses of mepo in EGPA and showed that there were improvements in clinical features, including GI, cardiac, purpura, as well as neurologic manifestations (all of which we classi...